

# Differential deletions of chromosome 3p are associated with the development of uterine cervical carcinoma in Indian patients

S Dasgupta, S B Chakraborty, A Roy, S Roychowdhury, C K Panda

*J Clin Pathol: Mol Pathol* 2003;**56**:263–269

**Background:** Deletions in chromosome 3 occur frequently in uterine cervical carcinoma (CA-CX). The common consensus regions deleted during CA-CX development are not well defined, and have not been correlated with tumour progression.

**Aims:** To define specific regions of chromosome 3 deleted during development of CA-CX and to correlate these with clinicopathological data.

**Methods:** Deletion mapping of chromosome 3 was done in seven cervical intraepithelial neoplasia (CIN) and 43 primary CA-CX samples using 20 highly polymorphic microsatellite markers.

**Results:** Deletions of chromosome 3 were significantly associated with tumour progression. High frequencies (33–53%) of loss of heterozygosity (LOH) were found in 3p26.1, 3p22.3, 3p21.2, and 3p13, suggesting the location of putative tumour suppressor genes (TSGs) in these regions. Among these four regions, deletions in 3p21.2 were suggested to occur early during CA-CX development. A significant correlation was found between LOH at 3p26.1 and 3p22.3 with tumour progression from stage I/IIb to stage III/IV. No association was found with the highly deleted regions and human papillomavirus positivity, parity, or menopausal status. Microsatellite size alteration was seen in only seven of the samples. However, rare biallelic alterations were seen in and around the highly deleted regions. Loss of normal copy of chromosome 3 and interstitial alterations in chromosome 3p were seen in some samples.

**Conclusion:** These four regions on chromosome 3p may be differentially deleted during specific stages of CA-CX development. The putative TSGs located in these regions may have a cumulative effect on tumour progression.

See end of article for authors' affiliations

Correspondence to:  
Dr C K Panda, Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, S.P. Mukherjee Road, Calcutta-700026, India; ckpanda@vsnl.net

Accepted for publication 26 May 2003

Globally, uterine cervical carcinoma (CA-CX) is the fifth most common cancer,<sup>1</sup> and each year there are approximately 450 000 new cases of invasive cervical cancer diagnosed (about 12% of all cancers in women), with 300 000 deaths from the disease (World Health Organisation 1996). CA-CX is the most common cancer among Indian women,<sup>2</sup> and approximately 1/5 to 1/6 of cervical cancers worldwide occur in India.<sup>3</sup>

Several possible contributory factors have been implicated in the development of CA-CX, such as the use of oral contraceptives, young age at marriage, multiparity, immunosuppression, low socioeconomic and educational status, multiple sex partners, smoking, and others.<sup>4–8</sup> However, no one has linked menopausal status with the incidence of CA-CX, although an association has been found between menopausal status and breast and biliary tract cancer.<sup>9–10</sup> Human papillomavirus (HPV) infection has been shown to be one of the most important aetiological factors in the development of CA-CX, particularly infection with high risk HPV types 16, 18, 33, and 42.<sup>11–14</sup> Because only a minority of HPV positive lesions progress to invasive cancer after a long latent period, additional somatic events, including the functional inactivation of tumour suppressor genes (TSGs) and activation of oncogenes, are thought to be required for malignant transformation.<sup>15–16</sup>

“Whereas gain on chromosome 3q may represent the presence of an oncogene at this locus, chromosomal losses might represent the location of putative tumour suppressor genes”

Cytogenetic analysis of CA-CX lesions, although limited, has revealed frequent non-random chromosomal aberrations, including deletions, amplifications, and isochromosome formation.<sup>16</sup> Comparative genomic hybridisation of cervical tumours has identified over-representation of chromosome 3q as a recurrent event in invasive tumours and under-representation of chromosomal arms 2q, 3p, 6p, 8p, 11q, and 13q during tumour progression.<sup>17–18</sup> Whereas gain on chromosome 3q may represent the presence of an oncogene at this locus, chromosomal losses might represent the location of putative TSGs.

Loss of heterozygosity (LOH) studies of primary CA-CX have shown allelic loss on several chromosomal arms, such as 3p, 6p, 11q, and 18q.<sup>19–20</sup> Although the involvement of chromosome 3p deletions in the development of CA-CX has been confirmed by LOH studies using chromosome specific probes, there are several discrepancies between the reports defining the commonly deleted regions and frequencies of LOH. Mullokandov and colleagues<sup>20</sup> found an overall frequency of 39% LOH at the 3p21.3, 3p22.1–24.1, and 3p25.1–25.3 regions, whereas Larson and colleagues<sup>21</sup> detected an overall frequency of 70% LOH in CA-CX, with the most frequent deletion being at the 3p14 region. However, the highest frequencies of LOH

**Abbreviations:** CA-CX, uterine cervical carcinoma; CIN, cervical intraepithelial neoplasia; FAL, fractional allele loss; HPV, human papillomavirus; LOH, loss of heterozygosity; MA, microsatellite size alteration; PCR, polymerase chain reaction; RCC, renal cell carcinoma; RFLP, restriction fragment length polymorphism; TSG, tumour suppressor gene

detected by Mitra *et al* were 40% and 32% at the 3p21.33–22.1 and 3q28–29 regions, respectively, in CA-CX samples from Indian patients using restriction fragment length polymorphism (RFLP) markers.<sup>19</sup> Some investigators reported a gradual increase in the deletion frequency of chromosome 3p alleles along with tumour progression using samples at different stages from the same individual, but no statistical correlations were made with the associated regions, probably because of the low sample number.<sup>22–23</sup> In addition to LOH, microsatellite size alteration (MA) is another genetic change that has been associated with several human cancers.<sup>24</sup> The mechanisms underlying MA are currently unknown, but they probably represent a form of genomic instability.<sup>24</sup> About 35% of CA-CX samples of Western origin have been shown to exhibit MA.<sup>22</sup> Hampton and colleagues<sup>25</sup> have demonstrated an association between ethnicity and aetiological factors and the chromosomal deletions seen in CA-CX development; the frequency of chromosome 4p deletion differed between CA-CX samples of Indian origin and those from patients of white/Hispanic/American black origin using the same RFLP probes. Until now, few attempts have been made to carry out deletion mapping of chromosome 3 in CA-CX samples from Indian patients using highly polymorphic microsatellite markers to evaluate the deletion pattern, in addition to localising the candidate TSGs associated with the development of this tumour.

Thus, in our present study, we have attempted to map the frequently deleted regions on chromosome 3 in 50 cervical lesions of Indian patients using 20 highly polymorphic microsatellite markers. The deletion pattern and MA were correlated with different clinicopathological parameters, such as clinical stage, HPV infection, and menopausal status, to investigate whether there is an association between any of these factors and chromosomal alterations.

## MATERIALS AND METHODS

### Sample collection and clinical data

Fifty freshly operated uterine cervical lesions from previously untreated and unrelated individuals with corresponding normal tissue or peripheral blood leucocytes were used for our analysis (table 1). The tissues were obtained from the patients treated at the hospital section of Chittaranjan National Cancer Institute, India after appropriate informed consent by the patients and approval of the protocol by the hospital authorities. The samples were frozen immediately after collection and stored at  $-80^{\circ}\text{C}$  until use.

Table 1 provides a detail clinical history of the patients. Clinically, the tumours were graded and staged according to the FIGO classification. The average age of the patients was recorded as 44 years, with a mean length of time married of 16 years and parity ranging from one to 10. Twenty three of the patients were premenopausal, whereas the remainder (27) were postmenopausal.

### Microdissection and DNA extraction

The normal cells present as contaminants in the primary uterine cervical lesions were removed by microdissection.<sup>26</sup> Samples containing  $< 60\%$  tumour cells were not analysed. High molecular weight genomic DNA was extracted from the tissues according to the standard procedure.<sup>26</sup>

### Selection of microsatellite markers

Twenty highly polymorphic microsatellite markers spanning the entire length of chromosome 3 (fig 1) were selected for our analysis. Fifteen markers were taken from the chromosome 3p region and five markers from 3q (fig 1). The SST marker from the chromosome 3q27.3 region was used as a control. All the markers showed  $> 69\%$  informativity in our samples (data not shown). The localisation and physical distance between the markers were obtained from <http://genome.ucsc.edu>,

except for D3S1289, in which case the information was obtained from the Genome Database.

### Microsatellite analysis and interpretation of LOH and MA

A standard polymerase chain reaction (PCR) analysis containing a [ $\gamma$ - $^{32}\text{P}$ ] ATP end labelled forward primer was performed in a 20  $\mu\text{l}$  reaction volume, as described by Dasgupta *et al*.<sup>26</sup> The DNA samples were amplified for 30 cycles in a thermal cycler (Techne, Cambridge, UK), comprising one minute at  $95^{\circ}\text{C}$ , one minute at the appropriate annealing temperature ( $50$ – $60^{\circ}\text{C}$ ), and two minutes at  $72^{\circ}\text{C}$ , followed by a final extension step at  $72^{\circ}\text{C}$  for seven minutes. The analysis of PCR products on denaturing polyacrylamide sequencing gels was performed as described by Dasgupta *et al*.<sup>26</sup> LOH was determined by densitometric scanning (CS-900; Shimadzu, Kyoto, Japan) of the autoradiographs. For informative cases, allelic loss was scored if there was complete loss of one allele or if the relative band intensity of one allele was decreased at least 50% in the tumour, compared with the same allele in the corresponding normal control. The value was calculated as the ratio of the band intensities of the larger to the smaller alleles in the tumour DNA divided by the same ratio in the corresponding normal DNA sample. An LOH index of  $> 1.5$  (loss of the smaller allele) or  $< 0.67$  (loss of the larger allele) corresponded to at least a 50% reduction in relative band intensities.<sup>27</sup> MA was scored as present if one or both alleles at a given locus showed size variation; that is, either expansion or contraction, in comparison with the same allele in normal control DNA.<sup>28</sup> When calculating LOH, samples showing homozygosity and MA only were not considered, whereas when calculating MA, the samples showing LOH only were not considered.<sup>29</sup> Those samples showing both LOH and MA at the same locus was considered for calculating both LOH and MA. All samples showing LOH and/or MA were subjected to repeat analysis after a second independent amplification for confirmation, and typed with additional RFLP markers (NAT-KpnI, Hb-HinfI, Hb-HincIII, CYP1A1-MspI, and ALAD-RsaI) to verify correct pairing of the samples.<sup>30</sup> In all cases, the results were in concordance with our findings (data not shown). This LOH/MA analysis procedure could detect LOH when 50% tumour DNA was present and MA when only 10–30% tumour DNA was present.<sup>26</sup>

### Detection of HPV-16 and HPV-18

The presence of HPV in the cervical lesions was detected by performing PCR using primers (MY09 and MY11) from the consensus L1 region.<sup>31</sup> Typing of HPV-16/18 in the L1 positive samples was done by means of PCR using specific primers from the E6 region of HPV-16<sup>32</sup> and the E7 region of HPV-18.<sup>33</sup> The PCR products were electrophoresed in 2% agarose gel, stained with ethidium bromide, visualised under ultraviolet light, and photographed. For final confirmation of the HPV types, after gel electrophoresis the PCR products were transferred on to a nylon membrane for Southern hybridisation with [ $^{32}\text{P}$ ] labelled HPV type specific probes.<sup>34</sup> DNA from the SiHa (for HPV-16) and HeLa (for HPV-18) cell lines and the HPV type specific plasmids were used as positive controls.

### Statistical analysis of the clinical data

We used multiple polymorphic markers ( $n = 20$ ) to investigate LOH at different regions of chromosome 3. For data analysis, we used two approaches: (1) for individual samples we determined the frequencies of LOH at individual chromosomal regions; (2) to determine whether the deletions in chromosome 3 were associated with the progression of the tumour, we determined frequencies of loss of individual markers using a fractional allele loss (FAL) index, as defined below by Wistuba and colleagues<sup>28</sup>:

$$3p \text{ FAL index} = \frac{\text{total number of chromosome 3 markers with LOH}}{\text{total number of informative chromosome 3 markers}}$$

**Table 1** Clinicopathological features and FAL index of uterine cervical carcinoma samples

Tumour	Age/Religion	Clinical stage	Histology	Years married	Menopausal status	Parity	HPV status	FAL index	Mean FAL index
310	40/H	CIN-I	Mild Dys	15	Pre	0+0	16	0.14	
4736	48/M	CIN-II	Mod Dys	15	Post	4+0	18	0	
4737	55/H	CIN-II	Mod Dys	18	Post	2+0	A	0	
2740	47/H	CIN-II	Mod Dys	20	Post	5+0	16	0.05	0.107
2661	42/H	CIN-III	Sev Dys	19	Post	3+0	16	0	
224	48/H	CIN-III	Sev Dys	13	Post	3+0	16	0.06	
930	40/H	CIN-III	Sev Dys	16	Post	3+0	16	0.5	
4725	50/H	I	WDSCC	16	Post	2+0	A	0	
3574	30/H	I	WDSCC	13	Pre	6+0	A	0.06	
2890	52/H	I	MDSCC	13	Post	5+0	16	0.06	
567	42/H	I	WDSCC	16	Pre	3+2	18	0.14	
1441	42/H	I	WDSCC	16	Pre	6+0	16	0.21	
3036	46/H	I	WDSCC	10	Pre	1+0	16	0.27	
3776	48/H	I	WDSCC	12	Post	5+0	16	0.35	
1684	46/H	I	WDSCC	22	Post	3+0	16	0.47	
1319	40/H	I	WDSCC	15	Post	5+0	16	1	
5210	60/H	IB	WDSCC	10	Post	10+0	16	0.19	
506	56/H	IB	WDSCC	17	Post	5+0	18	0	
1466	40/H	IB	MDSCC	10	Pre	4+0	18	0.07	
4251	65/H	IB	WDSCC	20	Post	4+0	A	0.08	0.196
3120	45/H	IB	MDSCC	18	Pre	3+0	16	0.14	
2753	48/H	IB	MDSCC	18	Post	8+0	16	0.17	
2884	60/H	IB	CIS	15	Post	3+0	16	0.29	
1118	43/H	IB	WDSCC	21	Pre	3+0	16	0.38	
2961	40/H	II	WDSCC	18	Pre	4+0	A	0.07	
4840	47/H	II	WDSCC	11	Post	4+0	18	0.08	
113	46/H	II	MDSCC	17	Pre	3+0	16	0.18	
4900	25/H	IIB	WDSCC	10	Pre	1+0	16	0	
5091	40/H	IIB	PDSCC	14	Pre	5+0	16	0.07	
5169	56/H	IIB	MDSCC	13	Post	6+0	A	0.13	
4849	40/H	IIB	WDSCC	10	Pre	6+2	16	0.25	
3493	40/M	IIB	WDSCC	25	Pre	2+0	16	0.25	
1145	48/H	III	WDSCC	18	Pre	5+0	16	0.07	
2756	45/H	III	MDSCC	19	Pre	4+0	16	0.28	
3221	38/H	III	WDSCC	24	Pre	2+0	18	1	
4320	30/H	IIIB	PDSCC	11	Pre	2+0	16	0.08	
3609	65/H	IIIB	MDSCC	20	Post	2+0	16	0.15	
2760	38/H	IIIB	WDSCC	17	Pre	3+0	18	0.2	
1178	60/H	IIIB	PDSCC	15	Post	3+0	16	0.27	
568	50/H	IIIB	MDSCC	14	Post	3+0	16	0.29	
54	47/H	IIIB	MDSCC	15	Post	5+0	16	0.31	0.343
1636	60/H	IIIB	WDSCC	13	Post	7+0	16	0.43	
1058	42/H	IIIB	PDSCC	19	Pre	1+0	16	0.53	
2060	65/H	IIIB	WDSCC	20	Post	6+0	16	0.61	
574	65/H	IV	WDSCC	13	Post	8+0	16	0.08	
4171	55/H	IV	PDSCC	13	Post	2+0	16	0.13	
3297	43/H	IV	WDSCC	20	Pre	4+0	16	0.13	
4839	38/M	IV	PDSCC	10	Pre	8+0	18	0.38	
666	50/M	IV	WDSCC	11	Post	7+0	16	0.53	
1879	40/H	IV	WDSCC	10	Pre	6+0	16	0.71	

Religion: H, hindu; M, muslim; Histology: Mod, moderate; Sev, severe; Dys, dysplasia; WDSCC, well differentiated squamous cell carcinoma; MDSCC, moderately differentiated squamous cell carcinoma; PDSCC, poorly differentiated squamous cell carcinoma; Menopausal status: Pre, premenopausal; Post, postmenopausal; HPV status: A, HPV absent; 16, HPV-16 present; 18, HPV-18 present. CIN, cervical intraepithelial neoplasia; FAL, fractional allele loss.

To correlate regional loss with the progression of the tumour, we calculated the mean FAL index for each histological category (table 1). The *t* statistic was used for comparison of the mean FAL index of these histological groups.

We performed  $\chi^2$  analysis to determine the association between LOH at highly deleted regions and different clinicopathological features, such as parity, the length of time married, menopausal status, HPV infection (table 2), and tumour stage (fig 2). A *p* value < 0.05 with Yates correction was considered to be significant.

## RESULTS


### Molecular abnormalities (LOH and MA) on chromosome 3

Deletion mapping of chromosome 3 in the primary cervical lesions revealed that 44 of the 50 samples showed LOH/MA for

at least one marker (figs 1, 3). All the 44 samples with alterations showed LOH, whereas only seven showed MA, indicating the importance of chromosome 3 deletions in the development of CA-CX. The allelic losses of chromosome 3 gradually increased with progression of the clinical stage, and there was a significant correlation between the mean FAL index (*p* < 0.05) and progression of the tumour (table 1).

The highest LOH frequencies of 33%, 53%, 48%, and 45% were detected at the chromosomal regions 3p26.1 (D3S1304), 3p22.3 (D3S1611), 3p21.2 (D3S1289/D3S3719), and 3p13 (D3S1284), respectively (fig 1). However, the highest frequency of MA (10%) was seen at the 3p22.1 (D3S3685) locus (fig 1). No sample showed high microsatellite instability; that is,  $\geq 40\%$  MA in the markers tested.

Four cervical lesions (930, 1319, 3221, and 1879) showed molecular abnormalities (LOH or MA) at all the informative



**Figure 1** Allele status of the chromosome 3 markers in the primary uterine cervical lesions. LOH, loss of heterozygosity; MA-1, microsatellite size alteration of one allele; MA-2, microsatellite size alteration of both alleles; LOH/MA, loss of one allele and size alteration of the other; RH, retention of heterozygosity; NI, non-informative; CIN, cervical intraepithelial neoplasia. D3S1297 is 1.9 Mb from chromosome 3p telomere.

loci, indicating loss of normal copy of chromosome 3 in these lesions (fig 1). Eight samples (1684, 3776, 4840, 3493, 2756, 1058, 2060, and 666) showed LOH and/or MA in more than two consecutive markers, particularly around the high LOH regions (fig 1). No homozygous deletion was found in these samples. However, five lesions (930, 4840, 4849, 1178, and 1879) showed rare biallelic alterations (MA-2 or LOH + MA) at four loci (fig 1) in and around the high LOH regions.

**Detection of HPV**

Forty four of the 50 cervical lesions were positive for HPV infection (table 1) using the consensus L1 primers. Among the HPV positive samples, 36 of 44 were positive for HPV-16 and eight of 44 were positive for HPV-18. No correlation was found between HPV infection with other clinicopathological parameters (data not shown).

**Clinical correlation of the molecular abnormalities (LOH/MA)**

Chi square analysis revealed a significant correlation between LOH at the 3p26.1 and 3p22.3 regions and clinical stage ( $p = 0.005-0.04$ ) and LOH at 3p21.2 with parity ( $p = 0.048$ ) (table 2). No such correlation was found between the four highly deleted regions mentioned earlier and other clinicopathological parameters, such as length of time married, menopausal status, and HPV infection (table 2). In addition, no association was found between the frequency of MA and different clinicopathological parameters (data not shown).


**DISCUSSION**

In our present study, we attempted to delineate a detailed deletion map of chromosome 3 in seven CIN lesions and 43 CA-CX lesions at different clinical and histological stages from an Indian patient population. We found that the short arm of

**Table 2** Clinicopathological correlation of the high LOH regions

Characteristics	3p26.1 region			3p22.3 region			3p21.2 region			3p13 region		
	LOH+	LOH-	p Value	LOH+	LOH-	p Value	LOH+	LOH-	p Value	LOH+	LOH-	p Value
Parity (0-3)	4	18	0.602	7	15	0.772	17	5	0.048	7	15	0.803
Parity (4-10)	8	20		10	18		14	14		8	20	
HPV+	12	32	<1	17	27	<1	29	15	0.274	14	30	0.775
HPV-	0	6		0	6		2	4		1	5	
Years married (10-17)	7	26	0.52	11	22	0.889	20	13	0.777	9	24	0.55
Years married (18-25)	5	12		6	11		11	6		6	11	
Premenopause	5	18	0.729	7	16	0.623	16	7	0.309	8	15	0.495
Postmenopause	7	20		10	17		15	12		7	20	

HPV, human papillomavirus; LOH, loss of heterozygosity.



**Figure 2** Pattern of deletions in the highly deleted regions of chromosome 3 during uterine cervical carcinoma progression. CIN, cervical intraepithelial neoplasia; LOH, loss of heterozygosity.


chromosome 3 was preferentially deleted during the development of CA-CX. The gradual increases in the mean FAL index from CIN to stage III–IV tumours were indicative of the accumulative nature of the deletions occurring in different chromosome 3 regions during progression of the tumour. Although a similar type of accumulative increase in the frequency of chromosome 3 deletions was observed during the development of CA-CX in a Western patient population,<sup>22,23</sup> and in the development of lung carcinoma,<sup>28</sup> the analysis procedure used in these studies was different to ours. Those investigators analysed CIN/dysplastic samples and invasive samples from the same individuals, whereas we analysed CIN and invasive samples from different individuals.

Among the four highly deleted regions, deletions in the 3p26.1 and 3p22.3 regions appeared to be associated with the development of stage III–IV CA-CX tumours because of a significant increase of LOH frequency compared with stage I–II tumours ( $p = 0.04$ – $0.005$ ) (fig 2). Although the deletion in

these two regions overlapped with the deleted regions seen in CA-CX tumours in other studies,<sup>21,23,35</sup> none of these investigators showed a significant association of the deletions with progression of the tumour. The marker D3S1304 on the 3p26.1 region used in our study is approximately 3.3 Mb further towards the telomere than the VHL gene, which is associated with the development of renal cell carcinoma (RCC) and related tumours.<sup>36</sup> Thus, VHL or another nearby gene might be involved in the progression of later stages of CA-CX tumours. The D3S1611 marker on the 3p22.1 region is intragenic to the mismatch repair gene MLH1.<sup>37</sup> However, we did not see a high frequency of MA in the cervical lesions studied. This indicates that the mutator phenotype might not be prevalent in the development of CA-CX. This observation corroborates well with other studies on this tumour.<sup>16</sup> Thus, the high frequency of allelic losses at the MLH1 locus suggests that apart from mismatch repair function, the deregulation of other possible functions of MLH1 (for example, homologous recombination, mediation of the G2 checkpoint, transcription coupled nucleotide excision repair, recognition of DNA damage, and apoptosis) might be associated with progression of the tumour.<sup>38</sup> However, the analysis of other genetic/epigenetic alterations (mutation, methylation, etc) of the MLH1 gene in cervical lesions is necessary to know the exact mechanism of inactivation of this gene. Adjacent to the MLH1 locus another TSG, DLC1, was found to be located about 1 Mb towards the centromere,<sup>39</sup> but its involvement in the development of CA-CX has not yet been studied.

“Deletions in the 3p26.1 and 3p22.3 regions appeared to be associated with the development of stage III–IV uterine cervical carcinoma tumours”

Deletion in the 3p21.2 region increased gradually from CIN to stage III–IV tumours and this region showed the highest percentage of deletion of all the four highly deleted regions at every stage of disease (fig 2). Thus, it seems that deletion in the 3p21.2 region might be the earliest event among the four highly deleted regions. Similar to our results, Kersemackers



**Figure 3** Representative autoradiograph showing (A) loss of heterozygosity and (B) microsatellite size alteration at different marker loci on chromosome 3 in different samples. T, DNA from dysplastic/tumour cells after microdissection; N, corresponding normal tissue or peripheral blood leucocytes. Sample numbers are the same as in fig 1. Arrows indicate loss of the corresponding allele and the asterisks indicate size alteration of one or both alleles.

and colleagues<sup>40</sup> and Guo and colleagues<sup>23</sup> have detected a high frequency of LOH in this region in this tumour type. However, no candidate TSG has been identified in this region, although a cluster of candidate TSGs including FUS1, RASSF1, SEMA3F, ARP, and BAP1 are located about 3.0 Mb away, between the telomere and the D3S1289 locus of the 3p21.2 region.<sup>41</sup> Nevertheless, an association of these genes with the development of CA-CX has not yet been documented.

The absence of LOH at 3p13 in CIN lesions but the high incidence of LOH in later stages of carcinoma indicate that deletions in this region might be necessary for progression of the tumour from CIN to stage I–IIB (fig 2). This region overlaps with the homozygously deleted region observed at chromosome 3p12–13 in a cervical carcinoma cell line.<sup>42</sup> Similarly, Wong *et al* have identified 52% LOH at the 3p13 region in CA-CX tumours.<sup>43</sup> The chromosome 3p12–14 region has been shown to suppress the tumorigenicity of an RCC cell line in a microcell hybrid system, suggesting the presence of a candidate TSG in this region.<sup>36</sup> Two candidate TSGs, NRC1 and ROBO1/DUTT1, associated with the development of RCC and lung cancer, respectively, are located in the 3p12–14 region.<sup>44,45</sup> However, we did not see high LOH in the ROBO1/DUTT1 locus using the adjacent marker D3S1274, although we have seen high LOH in this locus in primary head and neck squamous cell carcinoma.<sup>46</sup> The role of these genes in the development of CA-CX has not been analysed.

The low incidence (16%) of LOH in the D3S1300 locus, an intragenic marker of the FHIT gene, indicates that this gene is probably not associated with the development of CA-CX. However, using the same marker, Wistuba *et al* detected 56% LOH in this tumour type.<sup>22</sup> This difference in deletion frequency might result from differences in ethnicity, as reported by Hampton *et al*.<sup>25</sup> The involvement of this gene in the development of CA-CX cannot be ruled out completely without analysis of the mutation, methylation, and aberrant transcription profiles of this gene.

The presence of rare biallelic alterations in and around the high LOH regions indicates that the LOH/MA in one allele might impose some selective pressure on the other allele for deletion or size alteration, which would result in a growth advantage for the tumour. A similar type of phenomenon has also been seen in the allelotyping of chromosome 3 in primary head and neck squamous cell carcinoma samples in Indian patients.<sup>26</sup> The occurrence of interstitial alterations and loss of normal copy of chromosome 3 in some samples suggest that these chromosomal alterations are needed for progression of the tumour. These types of chromosomal abnormalities in chromosome 3 and 17 have also been reported in primary head and neck squamous cell carcinoma tumours.<sup>47,48</sup>

The high incidence (88%) of HPV infection in these samples suggests that HPV infection is a prerequisite for the development of cervical lesions. However, the absence of a significant correlation between HPV infection and the highly deleted regions indicates that HPV infection might have a causal association with the onset of CA-CX by affecting normal proliferation, differentiation, and apoptosis, and thus resulting in the accumulation of more mutations in the infected cells.<sup>49</sup>

Thus, it can be concluded from our analysis that the differential deletions in the four highly deleted regions seen in chromosome 3p in the uterine cervical lesions are necessary for the development of specific stages of CA-CX progression. The loss of function of TSGs located in these regions may have a sequential cumulative effect in the development of this tumour. In addition, Huebner<sup>50</sup> has suggested that compound mutations in different TSGs located in different chromosome 3p regions are necessary for the development of lung, kidney, and other cancers. Along with these deletions, other molecular changes in the chromosome, such as MA, biallelic alterations, interstitial alterations, and loss of normal copy of chromosome 3, might play some role in tumour progression by

### Take home messages

- Deletions of chromosome 3 were significantly associated with tumour progression
- High frequencies of loss of heterozygosity (LOH) were found in 3p26.1, 3p22.3, 3p21.2, and 3p13, suggesting the location of putative tumour suppressor genes in these regions, which may have a cumulative effect on tumour progression
- Deletions in 3p21.2 appear to occur early during cervical carcinoma development
- There was a significant association between LOH at 3p26.1 and 3p22.3 and tumour progression from stage I/IIB to stage III/IV
- These highly deleted regions were not associated with human papillomavirus positivity, parity, or menopausal status
- Microsatellite size alteration was seen in only seven of the samples

imposing some selective pressure that provides a growth advantage for the tumour.

### ACKNOWLEDGEMENTS

We are thankful to the Director, Chittaranjan National Cancer Institute (CNCI), Calcutta-700 026, India and Drs PS Basu, R Mondal, and S Mondal for their encouragement and help during this work. We are also grateful to Professor HZ Hausen and Dr EM de Villiers for their generous gift of HPV-16/18 plasmids. Financial support for this work was provided by grant number 27 (0111)/00/EMR-II from CSIR, Government of India.

### Authors' affiliations

**S Dasgupta, S B Chakraborty, C K Panda**, Department of Oncogene Regulation, Chittaranjan National Cancer Institute, 37, S. P. Mukherjee Road, Calcutta: 700026, India  
**A Roy**, Department of Pathology, Bankura Sammilani Medical College, Bankura, West Bengal, India  
**S Roychowdhury**, Department of Human Genetics, Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, Calcutta-700032, India

### REFERENCES

- 1 **Parkin DM**, Pisani P, Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. *Int J Cancer* 1993;**54**:594–606.
- 2 **Sankaranarayanan R**, Nair MK, Jayprakash PG, *et al*. Cervical cancer in Kerala: a hospital registry-based study on survival and prognostic factors. *Br J Cancer* 1995;**72**:1039–42.
- 3 **Murthy NS**, Mathew A. Screening for cancer of the uterine cervix and approaches adopted in India. *Indian J Cancer* 1999;**36**:154–62.
- 4 **Brinton LA**, Fraumeni JF, Jr. Epidemiology of uterine cervical cancer. *J Chronic Dis* 1986;**39**:1051–65.
- 5 **Ponten J**, Adami HO, Bergstrom R, *et al*. Strategies for global control of cervical cancer. *Int J Cancer* 1995;**60**:1–26.
- 6 **Schiffmann MH**, Brinton AB. The epidemiology of cervical cancer. *Cancer* 1995;**76**:1888–901.
- 7 **Franco EL**. Epidemiology in the study of cancer. *Encyclopedia of Cancer* 1997;**1**:621–41.
- 8 **Yliotalo N**, Sorensen P, Josefsson A, *et al*. Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. *Int J Cancer* 1999;**81**:365–75.
- 9 **Azzena A**, Zen T, Ferrara A, *et al*. Risk factor for breast cancer. Case-control study results. *Eur J Gynaecol Oncol* 1994;**15**:386–92.
- 10 **Tavani A**, Negri E, La Vecchia C. Menstrual and reproductive factors and biliary tract cancers. *Eur J Cancer Prev* 1996;**5**:241–7.
- 11 **Zur Hausen**. Human papilloma virus. *Annu Rev Microbiol* 1994;**48**:427–47.
- 12 **Howley PM**. Papillomavirinae. The viruses and their replication. In: Fields BN, Knipe DM, Howley PM, eds. *Virology*, Vol. 2. Boston: Harvard University, 1995:2045–76.
- 13 **Shah KV**, Howley PM. Papilloma viruses. In: Fields BN, Knipe DM, Howley PM, eds. *Virology*, Vol. 2. Boston: Harvard University, 1995:2077–109.
- 14 **Zur Hausen**. Papilloma virus causing cancer: evasion from host cell control in early events in carcinogenesis. *J Natl Cancer Inst* 2000;**92**:690–8.
- 15 **Larson AA**, Kern S, Sommers RL, *et al*. Analysis of replication error phenotypes in cervical carcinoma. *Cancer Res* 1996;**56**:1426–31.
- 16 **Lazo PA**. The molecular genetics of cervical carcinoma. *Br J Cancer* 1999;**80**:2008–18.

- 17 **Heselmeyer K**, Schrock E, du Manoir S, *et al.* Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. *Proc Natl Acad Sci U S A* 1996;**93**:479–84.
- 18 **Allen DG**, White DJ, Hutchins AM, *et al.* Progressive genetic aberrations detected by comparative genomic hybridisation in squamous cell cervical cancer. *Br J Cancer* 2000;**83**:1659–63.
- 19 **Mitra AB**, Murty V, Li RG, *et al.* Allelotype analysis of cervical carcinoma. *Cancer Res* 1994;**54**:4481–7.
- 20 **Mullokandov MR**, Kholodilov NG, Atkin NB, *et al.* Genomic alteration in cervical carcinoma: losses of chromosome heterozygosity and human papilloma virus tumor status. *Cancer Res* 1996;**56**:197–205.
- 21 **Larson AA**, Kern S, Curtiss S, *et al.* High resolution analysis of chromosome 3p alterations in cervical cancer. *Cancer Res* 1997;**57**:4082–90.
- 22 **Wistuba II**, Montellao FD, Milchgrub S, *et al.* Deletions of chromosome 3p are frequent and early events in the pathogenesis of uterine cervical carcinoma. *Cancer Res* 1997;**57**:3154–8.
- 23 **Guo Z**, Hu X, Afink G, *et al.* Comparisons of chromosome 3p deletions between cervical precancer synchronous with and without invasive cancer. *Int J Cancer* 2000;**86**:518–23.
- 24 **Fishel R**. Genomic instability, mutators, and the development of cancer: is there a role for p53? *J Natl Cancer Inst* 1996;**88**:1608–9.
- 25 **Hampton GM**, Larson AA, Baergen RN, *et al.* Simultaneous assessment of loss of heterozygosity at multiple microsatellite loci using semi-automated fluorescence-based detection: subregional mapping of chromosome 4 in cervical carcinoma. *Proc Natl Acad Sci U S A* 1996;**93**:6704–9.
- 26 **Dasgupta S**, Mukherjee N, Roy S, *et al.* Mapping of the candidate tumor suppressor genes' loci on human chromosome 3 in head and neck squamous cell carcinoma of Indian patient population. *Oral Oncol* 2002;**38**:6–15.
- 27 **Melamed J**, Einhorn JM, Ittamann MM. Allelic loss on chromosome 13q in human prostate carcinoma. *Clin Cancer Res* 1997;**3**:1867–72.
- 28 **Wistuba II**, Behrens C, Milchgrub S, *et al.* Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. *Oncogene* 1999;**18**:643–50.
- 29 **Dillon EK**, Boer WB, De Papadimitriou JM, *et al.* Microsatellite instability and loss of heterozygosity in mammary carcinoma and its probable precursors. *Br J Cancer* 1997;**76**:156–62.
- 30 **Ishwad CS**, Ferrel RE, Rossie KM, *et al.* Microsatellite instability in oral cancer. *Int J Cancer* 1995;**64**:332–5.
- 31 **D'Costa J**, Saranath D, Dedhia P, *et al.* Detection of HPV-16 genome in human oral cancers and potentially malignant lesions from India. *Oral Oncol* 1998;**34**:413–20.
- 32 **Park JS**, Dong SM, Kim HS, *et al.* Detection of p16 gene alteration in cervical cancer using tissue microdissection and LOH study. *Cancer Lett* 1999;**136**:101–8.
- 33 **Balaram P**, Nalinakumari KR, Abraham E, *et al.* Human papilloma viruses in 91 oral cancers from Indian betel quid chewers—high prevalence and multiplicity of infections. *Int J Cancer* 1995;**61**:450–4.
- 34 **Gillison ML**, Koch WM, Capone RB, *et al.* Evidence for a causal association between human papilloma virus and a subset of head and neck cancers. *J Natl Cancer Inst* 2000;**92**:709–20.
- 35 **Chung GT**, Huang DP, Lo KW, *et al.* Genetic lesions in the carcinogenesis of cervical cancer. *Anticancer Res* 1992;**12**:1485–90.
- 36 **Kok K**, Naylor SL, Buys CHCM. Deletion of the short arm of chromosome 3 in solid tumors and the search for tumor suppressor genes. *Adv Cancer Res* 1997;**71**:27–92.
- 37 **Papadopoulos N**, Nicolaidis NC, Wei YF, *et al.* Mutation of a mtL homologue in hereditary colon cancer. *Science* 1994;**263**:1625–9.
- 38 **Benachou N**, Guiral S, Gorska-Flipot I, *et al.* Frequent loss of heterozygosity at the DNA mismatch repair loci hMLH1 and hMSH3 in sporadic breast cancer. *Br J Cancer* 1999;**79**:1012–17.
- 39 **Daigo Y**, Nishiwaki T, Kawasoe T, *et al.* Molecular cloning of a candidate tumor suppressor gene, DLC1, from chromosome 3p21.3. *Cancer Res* 1999;**59**:1966–72.
- 40 **Kersemakers AM**, Hermans J, Fleuren GJ, *et al.* Loss of heterozygosity for defined regions on chromosome 3, 11 and 17 in carcinomas of the uterine cervix. *Br J Cancer* 1998;**77**:192–200.
- 41 **Zabarovsky ER**, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. *Oncogene* 2002;**21**:6915–35.
- 42 **Aburatani H**, Wang Y, Shibata H, *et al.* Identification of a region of homozygous deletion in cervical carcinoma [abstract]. *Am J Hum Genet* 1994;**55**:A51.
- 43 **Wong WF**, Chung TK, Cheung TH, *et al.* Frequent loss of heterozygosity of chromosome 3 short arm detected by PCR based microsatellite polymorphism in cervical squamous cell carcinoma. *Cancer Lett* 1997;**115**:161–4.
- 44 **Sundaresan V**, Chung G, Heppel-Parton A, *et al.* Homozygous deletion at 3p12 in breast and lung cancer. *Oncogene* 1998;**17**:1723–9.
- 45 **Lovell M**, Lott ST, Wong P, *et al.* The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. *Cancer Res* 1999;**59**:2182–9.
- 46 **Chakraborty SB**, Dasgupta S, Roy A, *et al.* Differential deletions in chromosome 3p are associated with the development of head and neck squamous cell carcinoma from Indian patients. *Cancer Genet and Cytogenet* [In press.]
- 47 **Scholes AGM**, Woolger JA, Boyle MA, *et al.* Synchronous oral carcinomas: independent or common clonal origin? *Cancer Res* 1998;**58**:2003–6.
- 48 **Adamson R**, Jones AS, Field JK. Loss of heterozygosity studies on chromosome 17 in head and neck cancer using microsatellite markers. *Oncogene* 1994;**9**:2077–83.
- 49 **Munger K**, Heselmeyer K. The molecular pathogenesis of cervical cancer; the role of human papilloma virus. In: Gazdar A, Srivastava S, Henson DE, *et al.*, eds. *Molecular pathology of early cancer*. Amsterdam: IOS Press, 1999:97–111.
- 50 **Huebner K**. Tumor suppressor on 3p: a neoclassic quartet. *Proc Natl Acad Sci U S A* 2001;**98**:14763–5.